Search Results

You are looking at 181 - 190 of 817 items for :

  • "screening" x
Clear All
Full access

Emma Gargus, Rebecca Deans, Antoinette Anazodo and Teresa K. Woodruff

imposed. A comprehensive literature search was performed in January 2018, with suitable studies identified through the electronic databases Medline, Embase, PsycInfo, Web of Science, and Scopus, alongside the screening of reference lists. Search terms

Full access

Benjamin E. Greer, Wui-Jin Koh, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, David K. Gaffney, Warner K. Huh, Daniel S. Kapp, John R. Lurain III, Lainie Martin, Mark A. Morgan, Robert J. Morgan Jr., David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr., Nelson Teng and Fidel A. Valea

Clinical Practice Guidelines in Oncology [NCCN Guidelines] for Cervical Cancer Screening, in this issue; to view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org ). 8 – 12 Other epidemiologic risk factors associated

Full access

Aatur D. Singhi, Siraj M. Ali, Jill Lacy, Andrew Hendifar, Khanh Nguyen, Jamie Koo, Jon H. Chung, Joel Greenbowe, Jeffrey S. Ross, Marina N. Nikiforova, Herbert J. Zeh, Inderpal S. Sarkaria, Anil Dasyam and Nathan Bahary

are characterized by young patient age at presentation, an absence of KRAS mutations, and a clinical response to ALK inhibitors. Considering the low prevalence of ALK rearrangements in PDAC, screening for these “actionable” targets may be

Full access

Brian Badgwell

also differences in the stage at presentation (primarily due to widespread screening in Japan and South Korea), surgical technique, and adjuvant therapy. Because of these differences, it is difficult to compare patients between regions based on stage

Full access

Yvonne Bombard, Peter B. Bach and Kenneth Offit

testing for mutations in BRCA1 or BRCA2 in unaffected women to identify those at significantly elevated risk for developing breast and ovarian cancer, 6 and screening patients with newly diagnosed colorectal cancer for mutations in mismatch repair

Full access

Julia R. Trosman, Christine B. Weldon, Michael P. Douglas, Allison W. Kurian, R. Kate Kelley, Patricia A. Deverka and Kathryn A. Phillips

medical necessity of specific suspected genes, and will likely lead to indiscriminant genetic screening (91%). However, they signaled their willingness to expand testing populations and relax testing criteria if evidence of Table 2. Payers

Full access

Monira Alwhaibi, Usha Sambamoorthi, Suresh Madhavan, Thomas Bias, Kimberly Kelly and James Walkup

providers need to screen for depression, especially among individuals with CRC and those diagnosed with an advanced cancer stage. Because cancer is a dominant condition and most of the care is usually directed toward treating cancer, such screening is

Full access

Michael J. Hassett, Wei Jiang, Melissa E. Hughes, Stephen Edge, Sara H. Javid, Joyce C. Niland, Richard Theriault, Yu-Ning Wong, Deborah Schrag and Rinaa S. Punglia

in situ of the breast. Results of a randomised trial in a population offered mammography screening . Acta Oncol 2006 ; 45 : 536 – 543 . 16. Habel LA Daling JR Newcomb PA . Risk of recurrence after ductal carcinoma in situ of the breast

Full access

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook and Christopher Willett

invasive cancer? Gastroenterology 1986 ; 91 : 419 – 427 . 45 Winawer SJ Fletcher RH Miller L . Colorectal cancer screening: clinical guidelines and rationale . Gastroenterology 1997 ; 112 : 594 – 642 . 46 Balthazar EJ Megibow

Full access

Grace L. Smith, Maria A. Lopez-Olivo, Pragati G. Advani, Matthew S. Ning, Yimin Geng, Sharon H. Giordano and Robert J. Volk

.G. Advani) performed title and abstract screening, full-text review, and consensus resolution of interrater discrepancies for inclusion (kappa, 0.79). Two reviewers for each study (G.L. Smith, P.G. Advani, M.S. Ning) abstracted and cross-checked study